Trial Profile
Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 07 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Jun 2009 New trial record.